Treatment
Conditions
Keywords
SBRT, prostate cancer, Ga-68 PSMA PET/MR
Brief summary
The aim of this study is to test the safety and efficacy of integrated boost to the dominant intraprostatic nodule based on Ga-68 Prostate-Specific Membrane Antigen (PSMA) PET/MR in Stereotactic Body Radiation Therapy (SBRT) in localized prostate carcinoma in patients for whom the standard treatment is the irradiation of the entire prostate gland with or without seminal vesicles accompanied or not by hormonal therapy.
Detailed description
Radiotherapy is considered standard of care treatment for prostate cancer. In light of the accumulating clinical evidence favoring the use of hypo fractionation, SBRT regimen might constitute a much more convenient non-invasive and highly efficient outpatient therapy. Although the proposed extreme hypofractionated radiotherapy approach was expected to provide excellent local control of the primary prostate cancer, a proportion of patients with intermediate- or high-risk disease may have recurrences with local recurrence or distant metastasis in the future, requiring strategies to minimize systemic disease. Ga-68 PSMA PET/MR has high accuracy in the diagnosis and staging of prostate cancer. In this protocol, pretreatment Ga-68 PSMA PET/MR and CT scanning were performed in all patients as well as the imaging fusion before delineating the target. This study would explore the simultaneously integrated boost or equential integrated boost to the dominant intraprostatic nodule based on Ga-68 PSMA PET/MR in SBRT.
Interventions
RADIATIONStereotactic Body Radiation Therapy (SBRT)
Very Low, Low, favorable, or Good Prognostic Intermediate prostate cancer:SBRT; Unfavorable, or Poor Prognostic Intermediate prostate cancer: SBRT accompanied 4 months ADT;High or Very High prostate cancer: SBRT accompanied 2 years ADT.
Sponsors
Changhai Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed adenocarcinoma of the prostate * tumor clinical stage cT1-3N0M0 according to AJCC TNM 2017 * Without any treatment of prostate cancer including radiotherapy, ADT, chemotherapy, focal treatment, etc. * With the examination of Ga-68 PSMA PET/MR * International Prostate Symptom Score(IPSS）\<15 (alpha blockers allowed), without severe urethral obstruction symptoms * ECOG performance status 0-2 * Written informed consent according to ICH/GCP regulations before registration and prior to any trial specific procedures
Exclusion criteria
* Prior pelvic RT * A tumor located at less than 3 mm from the urethra or rectum when measured at the MRI * Tumor clinical stage cT4, with metastases including bone, lymph nodes or organ metastasis * Histologically confirmed neuroendocrine tumor or small cell carcinoma of the prostate * Severe or active co-morbidity likely to impact on the advisability of SBRT like severe liver or kidney dysfunction, etc. * Patients with other malignancies, or acute or other severe infections, with ulcerative colitis, inflammatory bowel disease, etc. * Patients who have participated in other clinical trials for less than three months * Patients have acute prostatitis or chronic prostatitis with urinary symptoms * Urine routine indicates obvious urinary system infection and no significant improvement after anti-infective treatment, or conversion to recurrent urinary system infection * Unsuitable to participate in this clinical trial judged by the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Probability of Acute genitourinary (GU) , gastrointestinal (GI) toxicity and erectile dysfunction | 90 days after the first fraction of radiotherapy treatment | Acute genitourinary (GU) , gastrointestinal (GI) toxicity and erectile dysfunction (ED) (grade 2 or more) according to the NCI CTCAE v4.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The Probability of Chronic genitourinary (GU) , gastrointestinal (GI) toxicity and erectile dysfunction (ED) | > 90 days and up to 3 years from the start of protocol treatment | Chronic genitourinary (GU) , gastrointestinal (GI) toxicity and erectile dysfunction (ED) (grade 2 or more) according to the NCI CTCAE v4.0. |
| 1-year Biochemical Progression-free Survival (bPFS) | Assessment at 1-year | Biochemical Progression-free Survival (bPFS) |
| 1-year Local Progression-Free-Survival(LPFS) | Assessment at 1-year | Local Progression-Free-Survival(LPFS) |
| 1-year Distant Metastasis Free Survival(DMFS) | Assessment at 1-year | Distant Metastasis Free Survival(DMFS) |
| 1-year Overall Survival (OS) | Assessment at 1-year | Overall Survival (OS) |
Countries
China
Contacts
Primary ContactHuojun Zhang, PhD
Backup ContactXianzhi Zhao, MD
Outcome results
None listed